DXCM News and Press, DexCom Inc. From 10/04/22

DexCom ( NASDAQ: DXCM ) said its Dexcom G7 Continuous Glucose Monitoring (CGM) system was now available for people with diabetes age two years and older in the U.K., Ireland, Germany, Austria and Hong Kong. The company is also working to launch G7 in New Zeal...

People with diabetes in the United Kingdom, Ireland, Germany, Austria and Hong Kong can get started with Dexcom G7 now The new CGM system is also expected to launch in New Zealand and South Africa in the weeks ahead, with additional markets planned soon after A globa...

Summary Philippe Laffont’s 13F portfolio value decreased from $13.67B to $8.26B this quarter. They increased Amazon.com, JD.com, Enphase Energy, Alibaba Group Holdings, and Lucid Group while reducing Rivian Automotive, Visa, Snowflake, Sea Ltd., DoorDash, Nvidia, and Roblox...

Every portfolio could use a couple of evergreen stocks -- you know, the stocks issued by companies that can keep growing for years and years without making major changes to their business models or products. Commonly enough, evergreens have staying power because they're getting a steady boo...

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2022 financial results after market close on Thursday, October 27, 2022. Management will hold a conference call to review the company's third quarter 2022 performance starting at 4:30 p.m. (Eastern...

Growth stocks have received much of investors' ire throughout the current market downturn. With economic problems such as inflation lurking, investors are increasingly investing their money in safer companies rather than growth-oriented ones. The latter seem overvalued and sometimes generat...

The Nasdaq is down 27% this year, and that can be incredibly discouraging for growth investors. However, the tech-heavy index has still delivered impressive growth over a longer time frame. Over the past five years, the index remains up 77% vs. 54% for the S&P 500 . The moral of the...

Summary DexCom has been punished on the chart in FY22. Despite this, fundamentals remain strong with high levels of free cash flow and return on investment. Shares trade at lofty multiples but this is backed by the company's earnings and FCF trends. Net-net I rate DXCM a b...

Summary Today, we take our first look at DexCom, Inc., a designer, manufacturer, and marketer of various glucose monitoring systems. DexCom, Inc. stock has started to rebound recently, even after disappointing Q2 results. Can the rally continue? An investment analysis follows ...

Summary From 2017 to 2021, sales grew by an average of 36% per year. DexCom is growing strongly, developing and introducing top products to the market, but the stock is still highly valued. The stock has entered a bear market. Introduction DexCom ( DXCM ) has...